Fei Wu
Impact in
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- Cancer-related Molecular Pathways
- CAR-T cell therapy research
- Immunology top 5%
- Immunotherapy and Immune Responses
Papers in
-
- Ubiquitin and proteasome pathways 7
- Epigenetics and DNA Methylation 6
-
- Prostate Cancer Treatment and Research 5
- Renal cell carcinoma treatment 5
- Co-authors
- Jinfang Zhang (4 shared papers)Wenyi Wei (3 shared papers)Jianping Guo (3 shared papers)Xiangpeng Dai (3 shared papers)Piotr Siciński (2 shared papers)Yan Geng (2 shared papers)Yuyong Tan (2 shared papers)Yanpeng Ci (2 shared papers)
- Journals
- Cell Death and Disease (4 papers)PLoS ONE (3 papers)Theranostics (3 papers)Tumor Biology (3 papers)Frontiers in Oncology (3 papers)
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Fei Wu
101 papers receiving 2.3k citations
Fei Wu's Hit Papers
Peers
Comparison fields: 5 of 115
- Oncology 705
- Immunology 400
- Cancer Research 273
- Pulmonary and Respiratory Medicine 438
- Molecular Biology 972
Countries citing papers authored by Fei Wu
This map shows the geographic impact of Fei Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fei Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fei Wu more than expected).
Fields of papers citing papers by Fei Wu
This network shows the impact of papers produced by Fei Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fei Wu. The network helps show where Fei Wu may publish in the future.
Co-authors
The 25 scholars most cited alongside Fei Wu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 108 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance Hit paper breakdown → | 2017 | 761 |
| 2 | 2014 | 116 | |
| 3 | 2020 | 94 | |
| 4 | 2016 | 89 | |
| 5 | 2019 | 56 | |
| 6 | 2019 | 53 | |
| 7 | 2012 | 43 | |
| 8 | 2016 | 43 | |
| 9 | 2014 | 39 | |
| 10 | 2020 | 37 | |
| 11 | 2021 | 35 | |
| 12 | 2019 | 35 | |
| 13 | 2019 | 35 | |
| 14 | 2017 | 32 | |
| 15 | 2016 | 29 | |
| 16 | 2021 | 28 | |
| 17 | 2023 | 28 | |
| 18 | 2015 | 28 | |
| 19 | 2013 | 27 | |
| 20 | 2021 | 27 |
About Fei Wu
Fei Wu is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine, Oncology, Immunology and Endocrinology, Diabetes and Metabolism, having authored 108 papers that have together received 2.3k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (7 papers), Epigenetics and DNA Methylation (6 papers), CAR-T cell therapy research (6 papers), Prostate Cancer Treatment and Research (5 papers), Renal cell carcinoma treatment (5 papers), interferon and immune responses (4 papers), Hippo pathway signaling and YAP/TAZ (4 papers) and Cancer, Hypoxia, and Metabolism (4 papers). The work is most often cited by research in Oncology (705 citations), Immunology (400 citations), Cancer Research (273 citations), Pulmonary and Respiratory Medicine (438 citations) and Molecular Biology (972 citations). Fei Wu has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Jinfang Zhang, Wenyi Wei, Jianping Guo, Xiangpeng Dai, Piotr Siciński, Yan Geng, Yuyong Tan, Yanpeng Ci, Haizhen Wang and Yinghao Sun. Their work appears in journals such as Cell Death and Disease, PLoS ONE, Theranostics, Tumor Biology and Frontiers in Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.